The merger vote is the next key catalyst on October 26. Monitor for any last-minute opposition or changes in shareholder sentiment. The preclinical data is supportive but early-stage; focus on the deal timeline rather than the science for near-term trading.
Price Chart
Executive Summary
Eos SENOLYTIX presented positive preclinical survival and healthspan data for PTC-2105 at a conference, and launched a public engagement campaign. This 425 filing is a routine M&A communication updating the status of the proposed merger with Pulmatrix, which is on track for a shareholder vote on October 26, 2026, with closing expected shortly after. The data is preclinical and promotional, with no changes to deal terms or financials.
Key Financial Metrics
Key Facts
- PTC-2105 (25 mg/kg) showed statistically significant overall survival increase vs saline in aged mice (log-rank p=0.0142).
- Special meeting of Pulmatrix stockholders to vote on the merger is scheduled for October 26, 2026.
- Merger is anticipated to close shortly after the special meeting, subject to customary conditions.
- Combined company's common stock expected to trade on Nasdaq under ticker 'MTXL'.
- Eos is planning first-in-human studies followed by a Phase 1b trial in sarcopenia patients aged 60+.
- A 180-mouse study is underway to confirm a potentially concerning lifespan signal in semaglutide-treated mice.
Financial Impact
No financial figures reported; preclinical data only.
Risk Factors
- Stockholder approval of the merger is not guaranteed.
- Preclinical results may not translate to human clinical outcomes.
- Merger-associated financings are expected but not yet secured.
- Nasdaq listing of combined company is subject to satisfaction of conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-047966 |
| Document: 0001493152-26-047966-index-headers.html | 0001493152-26-047966 |
| Document: 0001493152-26-047966-index.html | 0001493152-26-047966 |
| Document: 0001493152-26-047966.txt | 0001493152-26-047966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 5d ago | EFFECT | $1.48 | awaiting T+5 | awaiting T+5 | $1.43 (+3.36%) |
Oct 22, 2026 6d ago | 425 | $1.42 | awaiting T+5 | awaiting T+5 | $1.43 (+0.72%) |
Oct 13, 2026 15d ago | 425 | $1.38 $1.43 | ▲ +3.62% | ▲ +4.77% | $1.43 (+3.64%) |
Oct 7, 2026 20d ago | DEFA14A | $1.53 $1.41 | ▼ −7.67% | ▼ −7.39% | $1.43 (−6.35%) |
Oct 2, 2026 25d ago | S-3/A | $1.48 $1.43 | ▲ +3.38% | ▲ +3.80% | $1.43 (+3.36%) |
Sep 28, 2026 4w ago | EFFECT | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.43 (+10.05%) |
Sep 25, 2026 4w ago | DEFM14A | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.43 (+10.05%) |
Sep 23, 2026 4w ago | S-4/A | $1.67 $1.54 | ▼ −7.78% | ▼ −7.37% | $1.43 (−14.36%) |
Sep 22, 2026 5w ago | 425 | $1.69 $1.52 | ▼ −9.79% | ▼ −9.12% | $1.43 (−15.12%) |
Sep 17, 2026 5w ago | S-4/A | $1.44 $1.61 | ▲ +11.81% | ▲ +10.54% | $1.43 (−0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers